The introduction of second-generation androgen receptor antagonists (SG-ARAs) has
greatly impacted the treatment of metastatic prostate cancer, providing tolerable and …

The NR superfamily comprises 48 transcription factors in humans that control a plethora of
gene network programs involved in a wide range of physiologic processes. This review will …

Neuroendocrine prostate cancer is a histological variant of prostate cancer that is
characterized by aggressiveness, poor clinical outcomes, and expression of neuroendocrine …

The major challenge in the treatment of patients with advanced lethal prostate cancer is
therapeutic resistance to androgen-deprivation therapy (ADT) and chemotherapy …

The treatment landscape of advanced prostate cancer has widely expanded over the past
years with androgen receptor signaling inhibitors (ARSIs) and taxane chemotherapy moving …

Bacteriophages, also known as phages, are specific antagonists against bacteria. T7 phage
has drawn massive attention in precision medicine owing to its distinctive advantages, such …

Background While response rates to anti-PD1 therapy are low in unselected metastatic
castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations in …

In the absence of curative therapies, treatment of metastatic castrate-resistant prostate
cancer (mCRPC) using currently available drugs can be improved by integrating …

Prostate cancer (PCa) is the most diagnosed malignancy in the men worldwide. Cancer
stem cells (CSCs) are the sub-population of cells present in the tumor which possess unique …

Background Despite the advent of improved therapeutic options for advanced prostate
cancer, the durability of clinical benefits is limited due to inevitable development of …